Ferry A.L.M. Eskens

10.5k citations

161 papers · 6.4k indexed · 2 hit papers · h-index 43

Oncology top 0.5%
Molecular Biology top 2%
Pulmonary and Respiratory Medicine top 1%
Cancer Research top 1%
Hepatology top 1%

Co-authors: Jaap Verweij P Hinnen Ronald Hoekstra Maja J.A. de Jonge Ate van der Gaast Stefan Sleijfer Leni van Doorn Alex Sparreboom
Topics: Cancer Treatment and Pharmacology (31 papers)Colorectal Cancer Treatments and Studies (29 papers)Gastric Cancer Management and Outcomes (20 papers)
Cited by: Oncology Hepatology Cancer Research
Journals: Nature Communications Journal of Clinical OncologySHILAP Revista de lepidopterología
Partner nations: Netherlands United States United Kingdom

In The Last Decade

Ferry A.L.M. Eskens

159 papers receiving 6.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial

2014 465 citations Yoon‐Koo Kang, Ferry A.L.M. Eskens et al. profile →
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study

2019 400 citations Udai Banerji, Elisabeth G.E. de Vries et al. profile →

Peers

Countries citing papers authored by Ferry A.L.M. Eskens

Since Specialization

Citations

This map shows the geographic impact of Ferry A.L.M. Eskens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ferry A.L.M. Eskens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ferry A.L.M. Eskens more than expected).

Fields of papers citing papers by Ferry A.L.M. Eskens

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ferry A.L.M. Eskens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ferry A.L.M. Eskens. The network helps show where Ferry A.L.M. Eskens may publish in the future.

Co-authorship network of co-authors of Ferry A.L.M. Eskens

This figure shows the co-authorship network connecting the top 25 collaborators of Ferry A.L.M. Eskens. A scholar is included among the top collaborators of Ferry A.L.M. Eskens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ferry A.L.M. Eskens. Ferry A.L.M. Eskens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study 2025 ·Clinical Cancer Research ·Rahul Aggarwal,Sylvie Rottey,Alice Bernard‐Tessier,Begoña Mellado,Takeo Kosaka,Walter M. Stadler,Lisa G. Horvath,Richard Greil,Bert H. O’Neil,Bilal A. Siddiqui,Thomas Bauernhofer,Mehmet Asım Bilen,Ferry A.L.M. Eskens,Shahneen Sandhu,Crystal Shaw,Chia Hsin Ju,Benjamin E. Decato,(unknown),Ana M. Aparicio	0
2	Data from Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study 2025 ·Rahul Aggarwal,Sylvie Rottey,Alice Bernard‐Tessier,Begoña Mellado,Takeo Kosaka,Walter M. Stadler,Lisa G. Horvath,Richard Greil,Bert H. O’Neil,Bilal A. Siddiqui,Thomas Bauernhofer,Mehmet Asım Bilen,Ferry A.L.M. Eskens,Shahneen Sandhu,Crystal Shaw,Chia Hsin Ju,Benjamin E. Decato,(unknown),Ana M. Aparicio	0
3	A phase I dose-escalation study of LRP5/6 antagonist BI 905677 in patients with advanced solid tumors 2024 ·ESMO Open ·Heinz‐Josef Lenz,Guillem Argilés,Maja J.A. de Jonge,Rona Yaeger,Takefumi Doi,(unknown),Ferry A.L.M. Eskens,(unknown),(unknown),(unknown),Loes M. Pronk,Josep Tabernero	5
4	1550P Addressing uncertainties of clinical value and improving access for newly authorised indications through DRUG-Access Protocol (DAP)-like platforms: Joint collection and evaluation of real-world evidence 2024 ·Annals of Oncology ·Sahar Barjesteh van Waalwijk van Doorn-Khosrovani,(unknown),Hans Timmer,Karin Verkerk,Freek Verbeek,(unknown),Åslaug Helland,Bettina Ryll,(unknown),(unknown),Joselina Luzia Menezes Oliveira,Ulrik Lassen,Jean‐Yves Blay,Hans Gelderblom,Anna K.L. Reyners,Ferry A.L.M. Eskens,Egbert F. Smit,Emile E. Voest,Haiko J. Bloemendal	1
5	First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors 2022 ·Journal for ImmunoTherapy of Cancer ·Omid Hamid,Alberto Chiappori,John A. Thompson,Toshihiko Doi,Siwen Hu‐Lieskovan,Ferry A.L.M. Eskens,Willeke Ros,Adi Diab,Jean‐Philippe Spano,Naiyer A. Rizvi,Jeffrey S. Wasser,Eric Angevin,Patrick A. Ott,Alison Forgie,Wenjing Yang,Cen Guo,Jeffrey Chou,Anthony B. El-Khoueiry	37
6	Liver Decompensation as Late Complication in HCC Patients with Long-Term Response following Selective Internal Radiation Therapy 2021 ·Cancers ·(unknown),(unknown),Mark C. Burgmans,Daphne D. D. Rietbergen,Minneke J. Coenraad,Otto M. van Delden,Roel J. Bennink,Tim A. Labeur,Heinz‐Josef Klümpen,Ferry A.L.M. Eskens,Adriaan Moelker,Erik Vegt,Dave Sprengers,Nahid Mostafavi,Jan N.M. IJzermans,R. Bart Takkenberg	5
7	Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial 2021 ·European Journal of Cancer ·Robin L. Jones,César Serrano,Margaret von Mehren,Suzanne George,Michael C. Heinrich,Yoon‐Koo Kang,Patrick Schöffski,Philippe A. Cassier,Olivier Mir,Sant P. Chawla,Ferry A.L.M. Eskens,Piotr Rutkowski,William D. Tap,Teresa Zhou,Maria Roche,Sebastian Bauer	85
8	Intratumoral Comparison of Nanoparticle Entrapped Docetaxel (CPC634) with Conventional Docetaxel in Patients with Solid Tumors 2020 ·Clinical Cancer Research ·Florence Atrafi,Ruben A.G. van Eerden,(unknown),Esther Oomen‐de Hoop,Peter de Bruijn,Martijn P. Lolkema,Adriaan Moelker,Cristianne J.F. Rijcken,Rob Hanssen,Alex Sparreboom,Ferry A.L.M. Eskens,Ron H.J. Mathijssen,Stijn L.W. Koolen	45
9	Telatinib Is an Effective Targeted Therapy for Pseudomyogenic Hemangioendothelioma 2018 ·Clinical Cancer Research ·David G.P. van IJzendoorn,Stefan Sleijfer,Hans Gelderblom,Ferry A.L.M. Eskens,Geert J.L.H. van Leenders,Károly Szuhai,Judith V.M.G. Bovée	35
10	Autologous Dendritic Cells Pulsed with Allogeneic Tumor Cell Lysate in Mesothelioma: From Mouse to Human 2017 ·Clinical Cancer Research ·Joachim G.J.V. Aerts,Pauline L. de Goeje,Robin Cornelissen,Margaretha E.H. Kaijen-Lambers,Koen Bezemer,Cor H. van der Leest,Niken M. Mahaweni,André Kunert,Ferry A.L.M. Eskens,Cynthia Waasdorp,Eric Braakman,Bronno van der Holt,Arnold G. Vulto,Rudi W. Hendriks,Joost P. Hegmans,Henk C. Hoogsteden	71
11	BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal Cancer 2016 ·Clinical Cancer Research ·Al B. Benson,Igor Kišš,John Bridgewater,Ferry A.L.M. Eskens,Carolyn Sasse,Sandra Vossen,Ji‐Hong Chen,(unknown),Howard Ball,Anne Keating,Andrew Krivoshik	17
12	The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation 2015 ·Clinical Cancer Research ·Martijn P. Lolkema,Hilde Bohets,Hendrik‐Tobias Arkenau,Ann Lampo,Erio Barale-Thomas,Maja J.A. de Jonge,Leni van Doorn,Peter Hellemans,Johann S. de Bono,Ferry A.L.M. Eskens	68
13	Hepatocellular carcinoma: Dutch guideline for surveillance, diagnosis and therapy. 2014 ·PubMed ·Ferry A.L.M. Eskens,Karel J. van Erpecum,Koert P. de Jong,Otto M. van Delden,Heinz‐Josef Klümpen,Cornelis Verhoef,P. L. M. Jansen,Maurice A. A. J. van den Bosch,Alejandra Méndèz Romero,Joanne Verheij,Elisabeth Bloemena,Robert A. de Man	11
14	Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E7107 in Patients with Advanced Solid Tumors 2013 ·Clinical Cancer Research ·Ferry A.L.M. Eskens,Francisco Javier Ramos,Herman Burger,James P. O’Brien,Adelaida Piera,Maja J.A. de Jonge,Yoshiharu Mizui,Erik A.C. Wiemer,(unknown),José Baselga,Josep Tabernero	195
15	CYP3A422* Genotype and Systemic Exposure Affect Paclitaxel-Induced Neurotoxicity 2013 ·Clinical Cancer Research ·Anne‐Joy M. de Graan,Laure Elens,Jason A. Sprowl,Alex Sparreboom,Lena E. Friberg,Bronno van der Holt,Pleun J. de Raaf,Peter de Bruijn,Frederike K. Engels,Ferry A.L.M. Eskens,Erik A.C. Wiemer,Jaap Verweij,Ron H.J. Mathijssen,Ron H. N. van Schaik	91
16	A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors 2012 ·Clinical Cancer Research ·Udai Banerji,Leni van Doorn,Dionysis Papadatos-Pastos,Rebecca Kristeleit,Phillip Debnam,(unknown),Adam Stewart,Florence I. Raynaud,Michelle D. Garrett,Martin Toal,Leon Hooftman,Johann S. de Bono,Jaap Verweij,Ferry A.L.M. Eskens	64
17	Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors 2011 ·Clinical Cancer Research ·Ferry A.L.M. Eskens,Maja J.A. de Jonge,Pankaj Bhargava,Toshiyuki Isoe,Monette Cotreau,Brooke Esteves,Kunihiko Hayashi,Herman Burger,Maarten Thomeer,Leni van Doorn,Jaap Verweij	89
18	Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors 2009 ·Molecular Cancer Therapeutics ·Richard D. Baird,Jos Kitzen,Paul A. Clarke,André Planting,(unknown),Alison Reid,(unknown),Luis López Lázaro,Begoña de las Heras,Ian Judson,Stan B. Kaye,Ferry A.L.M. Eskens,Paul Workman,Johann S. de Bono,Jaap Verweij	33
19	Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study 2009 ·Clinical Cancer Research ·Constantijne H. Mom,Jaap Verweij,Corina N.A.M. Oldenhuis,Jourik A. Gietema,Norma Lynn Fox,R. Miceli,Ferry A.L.M. Eskens,Walter J. Loos,Elisabeth G.E. de Vries,Stefan Sleijfer	85
20	Phase I study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with 5-fluorouracil and leucovorin: A safe combination 2006 ·European Journal of Cancer ·Ronald Hoekstra,Filip De Vos,Ferry A.L.M. Eskens,Elisabeth G.E. de Vries,D. R. A. Uges,Raymond A. Knight,Robert Carr,Rod Humerickhouse,Jaap Verweij,Jourik A. Gietema	38

About Ferry A.L.M. Eskens

Ferry A.L.M. Eskens is a scholar working on Oncology, Hepatology and Pulmonary and Respiratory Medicine, having authored 161 papers that have together received 6.4k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (31 papers), Colorectal Cancer Treatments and Studies (29 papers) and Gastric Cancer Management and Outcomes (20 papers). The work is most often cited by research in Oncology (2.9k citations), Hepatology (694 citations) and Cancer Research (1.2k citations). Ferry A.L.M. Eskens has collaborated with scholars based in Netherlands, United States and United Kingdom. Frequent co-authors include Jaap Verweij, P Hinnen, Ronald Hoekstra, Maja J.A. de Jonge, Ate van der Gaast, Stefan Sleijfer, Leni van Doorn, Alex Sparreboom, Elisabeth G.E. de Vries and Erik A.C. Wiemer. Their work appears in journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact